Literature DB >> 9246186

Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells.

B Marples1, P Lambin, K A Skov, M C Joiner.   

Abstract

This manuscript reviews the low-dose survival work using the DMIPS cell analyser that has been carried out at the Gray Laboratory in the U.K. and the British Columbia Cancer Research Centre in Canada. It describes low dose hyper-radiosensitivity (HRS) detected after single doses of X-rays less than approximately 0.3 Gy and the subsequent increased radioresistant response (IRR) seen as the dose increases up to 1 Gy. Work is summarized from studies in V79 cells, normal human and human tumour cell lines and mutant cell lines deficient in DNA repair. The data are considered in light of the hypothesis that hyper-radiosensitivity and increased radioresistance reflect the existence of an inducible protective mechanism, possibly triggered by DNA damage.

Entities:  

Mesh:

Year:  1997        PMID: 9246186     DOI: 10.1080/095530097143725

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  20 in total

1.  Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Authors:  Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

2.  Radiobiological Response of Cervical Cancer Cell Line in Low Dose Region: Evidence of Low Dose Hypersensitivity (HRS) and Induced Radioresistance (IRR).

Authors:  Saikat Das; Rabiraja Singh; Daicy George; T S Vijaykumar; Subhashini John
Journal:  J Clin Diagn Res       Date:  2015-06-01

3.  Cytogenetic effect of low dose gamma-radiation in Hordeum vulgare seedlings: non-linear dose-effect relationship.

Authors:  Stanislav A Geras'kin; Alla A Oudalova; Jin Kyu Kim; Vladimir G Dikarev; Nina S Dikareva
Journal:  Radiat Environ Biophys       Date:  2006-12-15       Impact factor: 1.925

4.  Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.

Authors:  Maria C De Santis; Luigia Nardone; Barbara Diletto; Roberta Canna; Michela Dispinzieri; Lorenza Marino; Laura Lozza; Vincenzo Valentini
Journal:  Br J Radiol       Date:  2016-07-25       Impact factor: 3.039

5.  Effects of G2-checkpoint dynamics on low-dose hyper-radiosensitivity.

Authors:  Oluwole Olobatuyi; Gerda de Vries; Thomas Hillen
Journal:  J Math Biol       Date:  2018-04-20       Impact factor: 2.259

6.  MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer.

Authors:  E Bufi; P Belli; M Costantini; P Rinaldi; M Di Matteo; A Bonatesta; M C De Santis; L Nardone; D Terribile; A Mulé; L Bonomo
Journal:  Br J Radiol       Date:  2012-07-04       Impact factor: 3.039

7.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

8.  Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Authors:  Patrick Beauchesne; Valerie Bernier; Charlotte Carnin; Luc Taillandier; Mohamed Djabri; Laurent Martin; Xavier Michel; Jean-Philippe Maire; Toufic Khalil; Christine Kerr; Thierry Gorlia; Roger Stupp; Remy Pedeux
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

9.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

Review 10.  The risk linked to ionizing radiation: an alternative epidemiologic approach.

Authors:  C de Brouwer; R Lagasse
Journal:  Environ Health Perspect       Date:  2001-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.